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Abstract
Background: Interstitial cystitis (IC), a chronic bladder disease with an increasing incidence, is
diagnosed using subjective symptoms in combination with cystoscopic and histological evidence. By
cystoscopic examination, IC can be classified into an ulcerative and a non-ulcerative subtype. To
better understand this debilitating disease on a molecular level, a comparative gene expression
profile of bladder biopsies from patients with ulcerative IC and control patients has been
performed.
Results: Gene expression profiles from bladder biopsies of five patients with ulcerative IC and six
control patients were generated using Affymetrix GeneChip expression arrays (Affymetrix –
GeneChip® Human Genome U133 Plus 2.0). More than 31,000 of > 54,000 tested probe sets were
present (detection p-value < 0.05). The difference between the two groups was significant for over
3,500 signals (t-test p-value < 0.01), and approximately 2,000 of the signals (corresponding to
approximately 1,000 genes) showed an IC-to-healthy expression ratio greater than two. The IC
pattern had similarities to patterns from immune system, lymphatic, and autoimmune diseases. The
dominant biological processes were the immune and inflammatory responses. Many of the up-
regulated genes were expressed in leukocytes, suggesting that leukocyte invasion into the bladder
wall is a dominant feature of ulcerative IC. Histopathological data supported these findings.
Conclusion: GeneChip expression arrays present a global picture of ulcerative IC and provide us
with a series of marker genes characteristic for this subtype of the disease. Evaluation of biopsies
from other bladder patients with similar symptoms (e.g. patients with non-ulcerative IC) will
further indicate whether the data presented here will be valuable for the diagnosis of IC.
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Background
Interstitial cystitis (IC) is a chronic bladder disorder char-
acterized by a combination of symptoms including pelvic
pain, urinary urgency, and urinary frequency. The esti-
mated prevalence of IC ranges from 18 to over 400 cases
per 100,000 individuals, with a predominance of cases
found in women [1-3]. Upon cystoscopy, IC can be
divided into a classic disease with Hunner's ulcer and a
non-ulcerative disease [4-6]. The relationship between
these two subtypes is not known and it has been suggested
that they represent separate disease entities [5]. Patients
with classic IC are older and have a lower bladder capacity
than patients with non-ulcerative IC [5,6]. Histological
examination of bladder biopsies from classic IC patients
reveals mucosal ulceration and extensive inflammation
[4,7]. The etiology of IC is unknown, but many theories
have been proposed, including neurogenic inflammation
with mast cell activation; absorption of potentially toxic
substances across the urothelium; a deficient gly-
cosaminoglycan mucus layer and a "leaky" urothelium
triggering a chronic inflammatory reaction in the subepi-
thelial layers; or an allergic or autoimmune process [1,3].
There is no evidence that IC is caused by bacterial infec-
tion [1].
Because no molecular marker assay is available, IC today
is diagnosed by symptom assessment, physical examina-
tion, routine urine analysis, cystoscopy, and sometimes
bladder biopsy. The National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) elaborated a set
of inclusion and exclusion criteria for the diagnosis of IC
for research purposes [2]. Inclusion criteria require a cys-
toscopy under anesthesia positively identifying Hunner's
ulcer or glomerulations (bleedings of the bladder wall
upon hydrodistension). Other inclusion criteria are blad-
der pain and/or urinary urgency [2]. The NIDDK excludes
patients with a bladder capacity larger than 350 ml,
patients with a symptom duration of less than nine
months, patients with urinary frequency less than eight
times a day and with an absence of nocturia, and patients
who can successfully be treated with antimicrobials, uri-
nary antiseptics, anticholinergics or antispasmodics. The
NIDDK criteria can be fully satisfied by 40% of all IC
patients [8].
Mast cells may play a central role in the pathogenesis and
pathophysiology of IC [9-11]. Mast cells migrate into tis-
sue perivascular spaces, and upon activation secrete gran-
ule-stored or de novo-synthesized molecules that mediate
inflammatory reactions [9].
Research has focused on finding objective markers for this
disease. Urine analysis of IC patients who fulfilled the
NIDDK criteria showed an increase in antiproliferative
factor (APF), a decrease in heparin-binding epidermal
growth factor-like growth factor (HB-EGF), and an
increase in epidermal growth factor (EGF) [12]. APF, a gly-
cosylated nonapeptide [13], is the biomarker with the
most specificity for IC [14], suggesting its potential use in
diagnostic testing. However, no test for APF is commer-
cially available, and the regulation of APF production, as
well as APF's role in causing symptoms, are uncertain [3].
Many APF experiments were done with explanted epithe-
lial cells in culture [15] – a condition that only represents
one aspect of the in vivo situation. More potential IC
markers have been identified by urine analysis. These are,
for example, inter-alpha-trypsin inhibitor heavy chain H4
[16], neutrophil elastase [17], insulin-like growth factor
binding protein-3 [14], IL-6 [14] or glycoprotein GP51
[18].
Directly analyzing gene expression in bladder biopsies
allows us to use a different approach for the molecular
characterization of IC. We looked for any significant dif-
ferences in mRNA levels between bladder cells from IC
patients with ulcers vs. bladder cells from healthy con-
trols. Even though ulcerative IC represents only a fraction
of all IC patients, this criteria allows for examination of a
relatively homogenous patient population. The global
approach of gene expression arrays has offered new infor-
mation on ulcerative IC and has provided us with data for
defining a characteristic pattern of "marker genes" for this
subtype of the disease.
Results
Description of patients
To accurately define a characteristic pattern of "marker
genes", patient selection was crucial. Creating a relatively
homogenous patient population required including only
IC patients with Hunner's ulcer. Table 1 summarizes the
clinical characteristics of the five IC and the six control
patients selected for our study. All patients are white
females, and for all patients an acute bacterial infection
was excluded. In urine specimens collected prior to sur-
gery, no bacterial growth was found. Only one patient,
classic IC patient 15, had leukocytes in the urine sample.
Since this patient has very severe glomerulations, this was
due to acute bleeding rather than due to a urinary tract
infection. There also was no evidence for a chronic urinary
tract infection since PCR analyses of representative blad-
der biopsies were negative for a selection of bacterial or
viral pathogens (results not shown). Four control patients
did not have any symptoms related to IC, but underwent
vaginal prolapse surgery after biopsy removal. Two con-
trol patients, patient 2 and patient 10, had bladder-related
symptoms. Patient 2 had urgency and frequency for 20
months, only minor pain, and a bladder capacity of 400
ml. Thus, this patient meets the relaxed eligibility criteria
for the IC Database Study [19]. Histopathology data anal-
ysis from patient 2 shows an intact urothelium with aBMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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Table 1: Clinical characteristics of five IC patients and six control patients
IC patients control group p-value sig.
Age [year] Mean 78.0 59.2 0.052* ns
Standard dev. 7.5 13.2
Median 82.0 57.5
Minimum 68.0 40.0
Maximum 85.0 75.0
Duration of symptoms [month] Mean 32.6 7.7 0.143* ns
Standard dev. 23.6 10.8
Median 24.0 3.0
Minimum 13.0 0.0
Maximum 72.0 20.0
Frequency [/24 h] Mean 14 8 0.056* ns
Standard dev. 9 2
Median 10 7
Minimum 8 7
Maximum 30 11
Average volume [< 350 ml] 5/5 0/6 0.002§ s
Nocturia Mean 4 1 0.032* s
Standard dev. 2 1
Median 3 1
Minimum 2 0
Maximum 8 2
Pain, VAS [0–100] Mean 69.4 19.0 0.016* s
Standard dev. 9.4 26.0
Median 73.0 10.5
Minimum 55.0 0.0
Maximum 78.0 55.0
Urge, VAS [0–100] Mean 69.6 32.0 0.111* ns
Standard dev. 19.0 38.2
Median 76.0 26.0
Minimum 37.0 0.0
Maximum 83.0 76.0
Hunner's ulcer 5/5 0/6 0.002§ s
Glomerulations 4/5 0/6 0.015§ s
Bladder tumor 0/5 0/6 n.a.
Diverticulum 0/5 0/6 n.a.
* Mann-Whitney-test, significance level = 0.050
§ Chi-Square-test, significance level = 0.050
n.a.: not applicable
VAS: visual analogue scaleBMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
Page 4 of 17
(page number not for citation purposes)
slight increase in mast cell counts in the detrusor muscle,
suggesting a mild form of IC. Patient 10 did not meet the
inclusion criteria for the IC Database Study, having nei-
ther urgency nor frequency and a localized pain sensation
for only three months. Upon histopathological analysis,
patient 10 was diagnosed with Cystitis glandularis et cyst-
ica. IC patients with ulcers are relatively old and the age
difference between the two investigated patient groups
was close to statistical significance (p-value 0.052; Table
1). All patients except one (control patient 2) are post-
menopausal. Previous studies also report an older age for
ulcerative patient groups [5-7]. No common medical his-
tory was found among the patients. Of note is that one of
the classic IC patients has chronic polyarthritis, and
another has polymyalgia rheumatica, but none of the
patients have a history of a lymphatic disease.
Raw data evaluation
From each IC patient, two bladder biopsies were ana-
lyzed, one from an ulcer area ("ulcus"), and one from a
non-ulcer area ("ni"). The correlation plot shows the pair-
wise comparison of all chips (Figure 1). White or light
grey squares correspond to similar gene expression, and
black or dark-grey squares correspond to different gene
expression. Gene expression among the healthy control
group and also among the ulcerative group shows a good
correlation (light squares). A comparison of all IC patient
samples (ulcus and ni) with the healthy controls reveals a
Gene expression array correlation plot Figure 1
Gene expression array correlation plot. Gene expressions of 16 bladder biopsies were compared. Bladder tissue was 
taken from six healthy controls ("healthy") and from five IC patients ("ulcus" and "ni"). From each IC patient, two samples have 
been analyzed, one from an ulcer (ulcus) and one from a non-ulcer (ni) area. Only probe sets defined as "present" have been 
included in this comparison, and the metric was the Pearson correlation coefficient. White or light-grey squares represent a 
similar gene expression, and black or dark-grey squares represent a difference in gene expression. Ulcer tissue (ulcus); non-
ulcer tissue in patients with Hunner's ulcers (ni).BMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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clear difference in gene expression (dark squares). One
exception is patient sample 14 ni that has a gene expres-
sion similar to the healthy controls. Gene expression of
sample 15 ni is different from the other four ni samples: 4
ni, 12 ni, 13 ni and 14 ni. There are only minor differences
between ulcer and ni samples. Previous research has pri-
marily focused on areas of the bladder with the most
severe pathology [7,20,21]. However, the results from the
correlation plot (Figure 1) encouraged us to perform the
statistical evaluations (t-test) for the five ni samples (4 ni,
12 ni, 13 ni, 14 ni, 15 ni) in comparison to the six healthy
controls (2, 5, 7, 9, 10, 11).
GeneChip expression data analysis
GeneChip expression arrays were used to compare the
population of ulcerative IC patients (five ni samples) with
the population of healthy controls (six control samples).
From a total of 54,613 tested probe sets 31,579 (58%)
were found to be present (detection p-value < 0.05) (see
Additional file 1). The difference in mRNA levels between
the two groups is significant for 3,618 probe sets as deter-
mined by the t-test statistics (p-value < 0.01; false discov-
ery rate (FDR) 8.7%) (see Additional file 2). Using these
statistical constraints, we were able to focus on genes
expressed in the mid-to-high range (Figure 2). Of the
3,618 significant probe sets, 1,957 showed an IC (ni) to
healthy expression ratio greater than two (see Additional
file 3). This corresponds to 1,417 proteins that are poten-
tially over- or under-represented in ulcerative IC by a fac-
tor of two or more (see Additional file 4).
Interestingly, many of the 25 proteins with the highest IC-
to-healthy expression ratios are expressed in B-leukocytes
(Table 2, [22-31], see Additional file 5). Therefore, B-cell
invasion into the bladder wall could be proposed as a
dominant feature of ulcerative IC. Our results also show
that characteristic genes for T-lymphocytes are signifi-
cantly up-regulated in ulcerative IC; however, they do not
rank among the top 25. As urothelial cells can also be
involved in immune response [32], the possibility that
gene expressions in the urothelium make a minor contri-
bution to these findings cannot be excluded. However, the
urothelial cells represent only a small fraction of our
biopsy samples (see below). Strong evidence for B- and T-
cell infiltration came from cluster analysis using Geneves-
tigator [33]. This reference expression database and meta-
analysis system predicted the top 100 markers for both B-
and T-lymphocytes, respectively. The two lists of probe
sets were generated from the database independent of our
results (see Additional file 6 and Additional file 7). Inter-
estingly, many top markers are significantly up-regulated
in our ulcerative IC patient samples (Figures 3A, B) and
convincingly confirm B- and T-cell infiltration of the blad-
der wall. Nine of the top 25 gene expressions (IGHM,
MS4A1, FCRL3, IGHG1, PAX5, BLK, IGHA1, IGL@,
FCRLA; Table 2) were present in the top 100 probe sets for
B-lymphocytes (see Additional file 6).
Histopathology data
Biopsies of IC patients and control patients were also
investigated microscopically. Ideally, three layers of the
bladder wall, namely the urothelium (mucosa), the sub-
mucosa (lamina propria) and the muscularis propria
(detrusor muscle), are included in a single biopsy. Histo-
logical data of the biopsies from our IC patients showed a
complete (Figure 4A) or a partial (Figure 4C) denudation
of the urothelium, a feature commonly found in classic IC
[4,7,20]. Care was taken to remove biopsies of similar
sizes; however, the depths of the biopsies vary, as do the
relative ratios of the cell layers. For all IC patients, hema-
toxylin and eosin (HE) staining of representative bladder
sections confirmed a severe inflammation characterized
by lymphocyte and plasma cell invasion in the deeper
areas (muscularis propria) of the biopsies (Figures 4A, C).
These findings strongly support our gene expression data
and agree with previously reported results [4,7,20,21,34].
The submucosa of control patient 2 was covered by a
urothelial layer (Figure 4D). Even though the control
showed a minor unspecific subepithelial inflammation
(Figure 4D), deeper areas of the biopsy did not demon-
strate the severe leukocyte infiltration as found in ulcera-
tive IC (Figure 4C). Mastocytosis has been credited with a
central role in the pathogenesis and pathophysiology of
IC [9-11]. All of our classic IC patients showed an increase
in mast cells in the detrusor muscle and in the lamina pro-
pria (Figure 4B).
Important processes in ulcerative IC
The ermineJ software program identified gene ontology
(GO) categories that are overrepresented in the significant
genes found for ulcerative IC [35]. We examined overrep-
resentation of GO categories in the up- and down-regu-
lated genes separately. The significance of
overrepresentation of GO categories is much higher for
up-regulated genes than for down-regulated genes (Table
3). In the three ontologies "biological process," "molecu-
lar function," and "cellular component," the best overlaps
were found for the GO categories "immune system proc-
ess" (corrected p-value 1.88E-74), "signal transducer
activity" (corrected p-value 1.17E-22), and "plasma mem-
brane" (corrected p-value 1.26E-15), respectively (Table
3). These data support our findings of leukocyte infiltra-
tion in ulcerative IC. They furthermore suggest that chem-
otactic signals are recognized by receptors in the plasma
membrane of these cells, which in turn elicit an intracel-
lular signaling cascade eventually regulating gene expres-
sion.
In MetaCore analysis, immune reaction processes were
found to be dominant in ulcerative IC (Table 4). The topBMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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Scatter plot: ni-vs-healthy Figure 2
Scatter plot: ni-vs-healthy. The scatter plot illustrates the data selection set by the statistical requirements in the ni-vs-
healthy comparison. The average expression values of condition "healthy" (patients 2, 5, 7, 9, 10, 11; x-axis) and condition "ni" 
(patients 4, 12, 13, 14, 15; y-axis) were compared. For this graph, all normalized data (54,613 probe sets) were used. Grey dots 
correspond to "not present" probe sets (criteria for "present": detection p-value < 0.05). Black dots correspond to "presents", 
and blue dots correspond to "presents" and "significants" (criteria for "significant": p-value for differential expression < 0.01). 
Non-ulcer tissue in patients with Hunner's ulcers (ni).BMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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process found was "Cell adhesion_Leucocyte chemo-
taxis". The six cytokine/chemokine genes encoding
CXCL13, CCL18, IL-8, CCL19, CXCL6 and GROa rank
within the top seven genes of this process. Receptors and
adhesion molecules are also over-represented (see Addi-
tional file 8).
The two processes "BCR pathway" (B-cell antigen recep-
tor-pathway) and "TCR signaling" (T-cell antigen receptor
signaling) were found to be among the most significant
processes (Table 4). In TCR signaling, two signals of anti-
gen-presenting-cells are necessary to stimulate T-cells.
These are CD80/CD86 and class II MHC on the antigen
presenting cell, and CD28 and TCR on the T-cell [36]. The
genes encoding these proteins are overexpressed in our
array data.
In Figure 5, the map of the BCR pathway is shown with
the log ratios of the ni-samples over the healthy samples,
visualized as thermometers. Only pathway components
with red thermometers, indicating up-regulation in the ni-
samples, were found. The B-cell antigen receptor pathway
is involved in the development, survival and activation of
B lymphocytes [37]. Membrane immunoglobulins bind
to their specific antigens, and together with the CD79A/
CD79B heterodimer, transduce the signal via a cytoplas-
mic signaling cascade involving protein tyrosine kinases
Lyn and Btk and phospholipase γ (PLC-gamma), activat-
ing transcription factors NF-AT or NF-κ B. These factors in
turn play key roles in the induction of immune response
genes and inflammation [38]. A key regulatory element in
B-cell development is transcription factor PAX5 (19×
overexpressed; Table 2). Gene expression profile studies
in mouse models suggest that PAX5 is essential for B-cell
commitment [39,40]. PAX5 promotes B lymphopoiesis
by activating B-cell specific genes (among others Cd19
and Cd79a); is essential for V-DJ recombination of the Igh
locus; maintains B-cell fate in more mature cells; and
represses genes whose expression is not B-cell specific.
Even though these studies cannot not be directly com-
pared to our experiments, it is interesting to note that the
PAX5-dependent genes Cd19 and Cd79a were among the
highly expressed genes found in our study (12× and 14×
overexpressed, respectively; see Additional file 4).
Comparison of the gene expression profiles of ulcerative 
IC and other diseases
The GeneGo software program defines signature genes for
diseases by collecting all available data related to a certain
disease (e.g. mRNA expression, proteomics, metabo-
lomics, microRNA assays and other phenotypic data)
[41]. By using this computational tool, overlaps of our sig-
Table 2: Top 25 gene expressions in ulcerative IC
# gene symbol* protein protein name over-expression$
1 CHI3L1 CH3L1_HUMAN Chitinase-3-like protein 1 68
2 CXCL13 CXL13_HUMAN C-X-C motif chemokine 13 59
3 CR2, CD21 [22] CR2_HUMAN Complement receptor type 2 47
4 LTF TRFL_HUMAN Lactotransferrin 44
5 IGHM [23] IGHM_HUMAN Ig mu chain C region 37
6 MS4A1 [24] CD20_HUMAN B-lymphocyte antigen CD20 32
7 IGHG1 [25] IGHG1_HUMAN Ig gamma-1 chain C region 26
8 IGL@ [26] IGL@ immunoglobulin lambda locus 24
9 CCL18 CCL18_HUMAN C-C motif chemokine 18 23
10 FCRLA [27] FCRLA_HUMAN Fc receptor-like A 22
11 IGH@ [25] IGH@ immunoglobulin heavy locus 21
12 MGC29506 PACAP_HUMAN Proapoptotic caspase adapter protein 20
13 FCRL5 [28] FCRL5_HUMAN Fc receptor-like protein 5 20
14 IGHA1 [25] IGHA1_HUMAN Ig alpha-1 chain C region 19
15 PAX5 [29] PAX5_HUMAN Paired box protein Pax-5 19
16 FCRL3 [28] FCRL3_HUMAN Fc receptor-like protein 3 19
17 BLK [30] BLK_HUMAN Tyrosine-protein kinase BLK 19
18 NTN2L NET2_HUMAN Netrin-2-like protein 18
19 TDO2 T23O_HUMAN Tryptophan 2,3-dioxygenase 18
20 CLC LPPL_HUMAN Eosinophil lysophospholipase 16
21 IGHV1–69 [31] IGHV1–69 immunoglobulin heavy variable 1–69 16
22 RPL14 RL14_HUMAN 60S ribosomal protein L14 16
23 FCRL1 [28] FCRL1_HUMAN Fc receptor-like protein 1 16
24 AQP9 AQP9_HUMAN Aquaporin-9 15
25 IL8 IL8_HUMAN Interleukin-8 15
* Gene expressions characteristic for B-cells are typed in BOLD.
$ Data from Additional file 4; for more information see Additional file 5.BMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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nificant gene expression data with the signature genes of
other diseases can be identified, and the significance of
these overlaps can be determined.
The forty disease categories having the most similar gene
expression to that found in bladder biopsies of ulcerative
IC patients are summarized in Table 5. Immune system
diseases, lymphatic diseases and autoimmune diseases are
the most significant. These categories include different
numbers of proteins. Large categories, such as "immune
system diseases" (2,482 proteins, 582 of them signifi-
cantly regulated in ulcerative IC) are more general and
contain proteins also found in smaller, more specialized
categories. While these data do not imply a similar gene
expression in bladder biopsies of e.g. lymphoma and
ulcerative IC patients, the data suggest a relationship
between these two diseases, primarily due to the shared
importance of B-cell markers.
Differences in gene expression in ulcer tissue vs. non-ulcer 
tissue from patients with Hunner's ulcers ("ulcus-vs-ni")
The populations of five ulcer tissues (4, 12, 13, 14, 15)
and five non-ulcer tissues (4 ni, 12 ni, 13 ni, 14 ni, 15 ni)
were compared by GeneChip expression array analysis
("ulcus-vs-ni"). From a total of 54,613 tested probe sets
30,842 were found to be present (detection p-value <
0.05). The difference in mRNA levels between the two
groups was significant for 505 probe sets as determined by
the t-test statistics (p-value < 0.01; FDR 57.2%) (see Addi-
tional file 9). One hundred and fourteen of the 505 signif-
Heatmap visualization of the top 100 B- and T-cell markers Figure 3
Heatmap visualization of the top 100 B- and T-cell markers. Using a biomarker search with Genevestigator [33] we 
identified the top 100 probe sets that were specific for "B-lymphocytes" (A) and "T-lymphocytes" (B), respectively, and visual-
ized them as a heatmap. For each probe set the heatmap shows the log2-ratio against the average of our entire data set. For 
both the B- and T-lymphocytes, a large proportion of the probe sets was upregulated in "ni" and "ulcus" as compared to the 
healthy tissue. Additional file 6 (Blympho-top100 cluster) and Additional file 7 (Tlympho-top100 cluster) list the top 100 probe 
sets and their corresponding gene names. Ulcer tissue (ulcus); non-ulcer tissue in patients with Hunner's ulcers (ni).
A B healthy       ni         ulcus healthy       ni         ulcusBMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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icant probe sets showed an ulcer vs. non-ulcer expression
ratio greater than two (see Additional file 9).
The significantly up-regulated genes of the ulcus-vs-ni
comparison had the best overlaps with the GO categories
"wound healing" (GO:0042060) for "biological process"
(corrected p-value 0.04228), "glycosaminoglycan bind-
ing" (GO:0005539) for "molecular function" (corrected
p-value 0.06007) and "extracellular region"
(GO:0005576) for "cellular component" (corrected p-
value 1.35E-08) (ermine J analysis [35]).
Discussion
Our data provide a global picture of the differences
between mRNA levels of bladder biopsies from classic IC
patients and from healthy controls. In the ni-vs-healthy
comparison, non-ulcer tissue of classic IC patients (ni)
and tissue from healthy controls (healthy) have been
compared, and in the ulcus-vs-ni comparison, ulcer
(ulcus) and non-ulcer tissues (ni) have been compared.
The ni-vs-healthy comparison yielded over 3,500 signifi-
cant changes at an FDR of 8.7%, which means there is a
possibility that a discrete gene could be a false positive.
However, the majority of the detected changes can be
attributed to genuine differences in non-ulcer and healthy
Histopathology data Figure 4
Histopathology data. Representative histopathology findings of bladder biopsies from IC patient 15 (A, B), from IC patient 4 
(C), and from control patient 2 (D). (A) Cross-section of an entire biopsy (60× magnification). The HE stain shows a focally 
accentuated lymphoplasmocytic inflammatory infiltration. The inner bladder surface is denudated from the urothelial lining 
(lower right), thus showing an ulcer area. (B) Giemsa staining (200×). Arrowheads point to numerous mast cells in the mixed 
lymphoplasmocytic inflammatory infiltration. Blood vessels show active hyperemia with dilated lumina. There is evidence of a 
substantial interstitial edema. (C) The HE stain (100×) shows a marginal urothelial layer (on the left) and substantial inflamma-
tion in deep areas of the biopsy. (D) The HE stain (100×) shows the urothelial layer on the left side and signs of a mild unspe-
cific subepithelial inflammation.
A B
C D
500 μ μ μ μm 100 μ μ μ μmBMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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Table 3: Most significant GO categories in ulcerative IC
result file term ID count size p-value corrected p-value*
biological processes up immune system process GO:0002376 217 551 1.07E-77 1.88E-74
immune response GO:0006955 180 418 4.21E-71 7.41E-68
response to stimulus GO:0050896 308 1397 1.36E-44 2.39E-41
defense response GO:0006952 117 325 2.19E-36 3.84E-33
signal transduction GO:0007165 348 2177 1.36E-20 2.39E-17
cell communication GO:0007154 371 2387 5.63E-20 9.89E-17
inflammatory response GO:0006954 66 195 3.71E-19 6.51E-16
biological processes down transmembrane receptor protein serine/threonine 
kinase signaling pathway
GO:0007178 18 55 1.99E-07 3E-04
molecular functions up signal transducer activity GO:0004871 234 1200 1.48E-25 1.17E-22
receptor activity GO:0004872 170 854 3.00E-19 2.35E-16
molecular functions down sequence-specific DNA binding GO:0043565 46 293 1.32E-05 0.0104
cellular components up plasma membrane GO:0005886 228 1304 3.27E-18 1.26E-15
cellular components down none - - - - -
* Up-regulated GO categories with a corrected p-value < 1.3E-15 are listed, the top-down regulated GO category of the respective analysis is 
shown. For "cellular components down" no significant GO category has been found.
Table 4: The 20 most significant affected processes in ulcerative IC
#n a m e p-value ratio
1 Cell adhesion_Leucocyte chemotaxis 3.05E-18 78/206
2 Immune_Phagosome in antigen presentation 1.43E-14 81/248
3 Immune_TCR signaling 2.55E-14 59/154
4 Immune_Antigen presentation 3.33E-14 68/193
5 Immune_Phagocytosis 1.88E-13 72/217
6 Immune_BCR pathway 3.48E-13 53/137
7 Inflammation_Neutrophil activation 2.12E-12 71/222
8 Inflammation_NK cell cytotoxicity 2.66E-11 54/155
9 Inflammation_TREM1 signaling 6.44E-11 51/145
10 Chemotaxis 5.47E-10 47/135
11 Inflammation_Interferon signaling 3.21E-08 38/110
12 Inflammation_Histamine signaling 4.01E-08 60/215
13 Proliferation_Lymphocyte proliferation 2.52E-07 50/175
14 Inflammation_Amphoterin signaling 2.63E-07 38/118
15 Cytoskeleton_Regulation of cytoskeleton rearrangement 6.46E-07 51/185
16 Inflammation_IL-2 signaling 2.33E-06 33/104
17 Cell adhesion_Platelet aggregation 4.76E-06 46/171
18 Inflammation_IL-4 signaling 9.46E-06 34/115
19 Inflammation_Innate inflammatory response 1.76E-05 46/179
20 Inflammation_IgE signaling 1.79E-05 38/138BMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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tissue (see Additional file 2). In contrast, the ulcus-vs-ni
comparison yielded only 500 significant changes at an
FDR of 57.2%, meaning the likelihood is only about 50%
that a randomly picked "significant" gene is truly differen-
tially expressed in ulcer vs. non-ulcer tissue (see Addi-
tional file 9). This suggests that the ulcer and non-ulcer
tissue of patients with Hunner's ulcer have only small dif-
ferences in gene expression. An analysis with a signifi-
cantly larger set of patients would probably have the
statistical power to identify those changes more reliably.
Given our limited set of patients, we obtained a rather
unreliable set of approximately 500 differentially
expressed genes, and therefore, our results of the associ-
ated GO categories should be regarded as an indication of
how ulcer and non-ulcer biopsies may differ.
As the gene expression arrays used in our study cover all
known human mRNAs (over 47,000 transcripts), previ-
Map of BCR-pathway Figure 5
Map of BCR-pathway. The process "Immune_BCR pathway" turned out to be significant (p-value 3.48E-13) in ulcerative IC 
(MetaCore analysis). The map shows a B-cell with the signal transduction from the membrane receptors to the transcription 
factors in the nucleus. The five columns on the right of an individual signaling component indicate the expression results of the 
five patient samples (4 ni, 12 ni, 13 ni, 14 ni, 15 ni) relative to the healthy controls. Up-regulated gene expressions are shown in 
red.BMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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ous gene expression data on IC can be compared with our
results.
Keay and others have published microarray analysis data
investigating gene expression differences in explanted epi-
thelial cells from bladder biopsies [15]. They focused on
approximately 4,000 genes and compared differences
between IC patients (NIDDK criteria) and asymptomatic
controls, and differences between normal epithelial cells
treated with APF, or with mock APF. One of the 13 genes
discussed in their publication was significant in our ni-vs-
healthy comparison. This was "neutral amino acid trans-
porter B" which was, as in their results, down-regulated
(see Additional file 4). We anticipated only minor over-
laps between the data from their paper and our results
since histopathological data from our investigated blad-
der biopsies indicated that urothelial cells contribute only
a minor part of all cell types (Figure 4). Even if there were
differences in urothelial gene expression between our two
investigated subgroups, they might be too subtle to be
detected. Furthermore, many of the 13 genes were ubiqui-
tously expressed genes (e.g. cyclin D, stress-activated pro-
tein kinase JNK1, putative tRNA synthetase-like protein,
ribosomal protein L27a), and as we primarily examined
cell types other than epithelial cells, this must lead to dif-
ferent results.
Hurst and co-workers addressed the question of abnor-
malities in the urothelium of IC patients [42,43]. With a
set of immunostainings against proteoglycan core pro-
teins and differentiation markers, they investigated biop-
sies of 27 IC patients (NIDDK criteria) and five controls
having stress incontinence [42]. They scored their data
from -2 (most abnormal) to +2 (normal), and their find-
ings suggested abnormal differentiation in the IC urothe-
lium. Many of the proteins investigated in their study were
present in both IC and control biopsies, but were local-
ized at different sites (e.g. dense luminal staining vs. uni-
form distribution). Gene expression analyses of entire
biopsies, as performed in our study, give no information
on spatial distributions. Moreover, the amount of urothe-
lium was reduced in our biopsies, and the presence of a
protein and its respective mRNA will not necessarily need
to correlate. Taking these three points into account, it is
expected that genes encoding the proteins found by Hurst
would not be significantly regulated in our analysis. Inter-
estingly, two genes, keratin-20 and uroplakin-1b were con-
siderably up-regulated (20- and 11-fold, respectively) in
the healthy controls, in agreement with the findings of
Hauser et al. (keratin-20 or uroplakin staining in normal
urothelium, no keratin-20 or weak uroplakin staining in
most abnormal urothelium) [42].
Generally, the presence of mRNA and the presence of the
encoded protein do not need to correlate. Temporal and
spatial differences in expression are likely. Regulation of
mRNA translation, protein processing, protein stability
and protein translocation are all factors that influence a
direct correlation between an mRNA and its mature pro-
tein.
Inflammatory features in IC have been investigated by his-
tological analysis. Peeker and Fall [4,5] defined a clear pic-
ture of ulcerative or classic IC that included urothelial
spongiosis and detachment; subepithelial, perineural and
perivascular deposits of mononuclear cells; and a charac-
teristic mast cell response, with an increase of mast cells in
detrusor muscle and in the lamina propria. In addition,
other groups reported extensive bladder inflammation of
Table 5: Diseases with signature genes similar to the gene 
expression profile of ulcerative IC bladder biopsies
# disease p-value ratio
1 Immune System Diseases 1.02E-35 582/2482
2 Lymphoproliferative Disorders 1.38E-28 382/1498
3 Lymphatic Diseases 1.45E-28 388/1530
4 Immunoproliferative Disorders 1.86E-28 382/1500
5 Hemic and Lymphatic Diseases 2.93E-25 440/1867
6 Autoimmune Diseases 1.85E-23 299/1145
7 Lymphoma 5.93E-21 256/964
8 Leukemia 3.39E-20 280/1098
9 Bacterial Infections and Mycoses 1.36E-19 310/1265
10 Infection 2.47E-19 289/1159
11 Goiter 8.45E-19 59/117
12 Plasmacytoma 6.11E-18 122/367
13 Paraproteinemias 1.38E-17 121/366
14 Hematologic Diseases 1.74E-17 297/1234
15 Sarcoidosis 1.85E-17 56/113
16 Multiple Myeloma 5.93E-17 118/359
17 Hyperthyroidism 7.14E-17 54/109
18 Graves' Disease 9.56E-17 52/103
19 Exophthalmos 9.56E-17 52/103
20 Orbital Diseases 1.63E-16 52/104
21 Joint Diseases 2.37E-16 197/737
22 Blood Protein Disorders 2.38E-16 123/387
23 Leukemia, Lymphocytic 2.95E-16 148/502
24 Arthritis 4.92E-16 190/707
25 Hemorrhagic Disorders 6.28E-16 142/478
26 Lymphoma, Non-Hodgkin 6.64E-16 160/563
27 Diabetes Mellitus, Type 1 1.46E-15 116/364
28 Vascular Hemostatic Disorders 1.89E-15 124/401
29 Arthritis, Rheumatoid 2.18E-15 159/565
30 Connective Tissue Diseases 2.62E-15 286/1217
31 Rheumatic Diseases 3.94E-15 178/661
32 Gastroenteritis 6.14E-15 117/375
33 Lymphoma, B-Cell 9.28E-15 113/359
34 Inflammatory Bowel Diseases 1.21E-14 103/316
35 Crohn Disease 1.57E-14 64/157
36 Lupus Erythematosus, Systemic 1.68E-14 99/300
37 Hepatitis, Autoimmune 6.39E-14 21/25
38 Virus Diseases 9.56E-14 215/871
39 Intestinal Diseases 2.55E-13 312/1402
40 Lymphoma, Low-Grade 4.01E-13 30/49BMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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patients with ulcer [7,20]. With our restriction to classic IC
we were able to characterize a relatively homogenous
group of patients. While our data agreed with reported
histological findings, they additionally provided us with a
series of potential gene expression markers for this sub-
type of the disease.
The generation of a gene expression profile for non-ulcer-
ative IC is expected to be more difficult. In contrast to clas-
sic IC, literature regarding non-ulcerative IC described a
heterogeneous picture with respect to inflammation.
Peeker and Fall [4] selected their patients according to the
NIDDK criteria and reported no inflammatory signs and a
less prominent mast cell involvement in non-ulcerative
IC. Erickson et al. [44] also evaluated their patients
according to the NIDDK cystoscopic criteria. Severe
inflammation was seen in 30% of the patients who met
the criteria and in 23% who did not. Ulcers were reported
for only four patients (corresponding to 11% of the
patients who met the criteria). Also Denson et al. [21],
who used the NIDDK inclusion criteria, described mono-
nuclear infiltration as the most consistent histological fea-
ture (while only 1% of their patients had a Hunner's ulcer,
70% showed mild to severe inflammation). In another
study by Erickson et al. [7], up to 35% of the non-ulcera-
tive patients had severe inflammations.
We can conclude that patient evaluation and selection for
a gene expression profile of non-ulcerative IC is crucial
and challenging. Very likely, a careful subdivision of this
heterogeneous patient group will be indispensable to
obtain statistically significant results.
An interesting and unexpected result of our study was the
severe inflammatory infiltration at non-ulcer ("ni") sites
of a bladder with Hunner's ulcer (Figure 3, Additional file
3). In the literature, many research groups have not
focused on such tissue, but have instead analyzed biopsies
of the most severely affected part of the bladder (e.g.
[7,20,21]). Factors released from an ulcer region, or, more
generally, from an abnormal urothelium, may have para-
crine influences on surrounding cells. For example, TNF
alpha (6.5-fold overexpressed in our ni-vs-healthy com-
parison) plays a central role in pro-inflammatory para-
crine signaling and mediates the recruitment of cells
involved in inflammatory and wound healing responses
[45]. It was not clear to us why gene expression of biopsy
14 ni was similar to the healthy controls (Figure 1). A
potential reason might be a reduced paracrine signaling at
the location of biopsy.
Compared to controls, mast cell counts were 6- to 8-fold
higher in the detrusor muscle of classic IC, and 2- to 3-fold
higher in non-ulcerative IC [9-11].
Several reviews attribute a key role to mast cells in the
mediation of chronic inflammation. Signals released from
abnormal urothelium or penetrating through a damaged
urothelium may stimulate submucosal sensory nerves,
and recruit and activate inflammatory leukocytes includ-
ing mast cells. Upon activation, mast cells release pre-
formed mediators stored in granules (histamine, heparin,
neutral proteases), generate mediators by enzymatic
processing of membrane phospholipids (leukotrienes,
prostaglandins), and produce cytokines and chemokines
de novo (IL-6, IL-8, TNF and many others). Released
mediators initiate and maintain the recruitment of
inflammatory cells, promote angiogenesis and stimulate
fibrosis [9,46-48].
Upon histological analysis, mastocytosis in the deeper
areas of the bladder wall was found in all of our classic IC
patients. The concept outlined above describing the cen-
tral role of mast cells in inflammation may explain many
of our findings. Upon cystoscopy and bladder filling, the
bladder wall was found to be very fragile at many points,
not only at the sites of Hunner's ulcers (unpublished
observation).
Conclusion
GeneChip expression arrays with total-RNA isolated from
bladder biopsies provided molecular insights into ulcera-
tive IC. The comparison of IC patients with healthy con-
trols revealed approximately 1,000 genes with an IC-to-
healthy expression ratio greater than two. Most differences
in gene expression are not due to induction or repression
of individual genes, as is observed by stimulation of cell
cultures in vitro, but are rather a consequence of leukocyte
infiltration. The predominant process of ulcerative IC is
an extensive immune response. B-cell commitment and
the production of antibodies appear to be striking fea-
tures, and most likely distinguish this chronic sterile cysti-
tis from an acute infectious cystitis. Previous
histopathology data have shown that leukocyte infiltra-
tion was common in ulcerative IC. Our data clearly con-
firm these findings, and, additionally, provide us with a
pattern of potential molecular markers characterizing this
subtype of IC. Future studies analyzing bladder biopsies
of patients with similar symptoms, but not having ulcera-
tive IC, will be needed. This would include the compari-
son of our ulcerative IC data with data from patients
having non-ulcerative IC, urinary tract infection, bladder
cancer, urinary tract stones or chemical/radiation cystitis.
The assemblage and evaluation of such data would pro-
vide us with molecular information for a differential diag-
nosis of IC and other bladder diseases.BMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
Page 14 of 17
(page number not for citation purposes)
Methods
Patients and tissue samples
IC patients were evaluated according to the NIDDK crite-
ria. Before surgery, urine was collected by urinary catheter-
ization. Urine specimens were inoculated for bacterial
cultures and tested for bacterial growth. Standard clinical
and laboratory diagnostic procedures were performed.
Informed consent was obtained from all patients and a
self-completed questionnaire was filled out. Cystoscopy
and surgery were performed under general anesthesia.
Three to four cold-cup biopsies (20 mm3 size) from blad-
der tissue excluding the trigone were collected. Immedi-
ately after biopsy removal the bleeding was stopped by
heat-coagulation. Clinical research has been approved by
the ethics commission (Ethikkommission des Kantons
Thurgau, Switzerland) and was in compliance with the
Helsinki Declaration.
Tissue storage and RNA isolation
At surgery, biopsies were submerged in 1 ml RNAlater
(76104, QIAGEN, Valencia, CA, USA) and stored accord-
ing to the manufacturer. For RNA isolation, biopsies were
transferred to 600 μl RLT buffer (RNeasy Mini Kit 74104,
QIAGEN, Valencia, CA, USA) containing 143 mM β-mer-
captoethanol and homogenized with the Dispomix sys-
tem (Medic Tools, Zug, Switzerland) using mechanical
disruption conditions of 4 × 15 sec at 4000 rpm. After
incubation at room temperature for 15 minutes and cen-
trifugation at 10,000 × g for 3 minutes, the supernatant
was treated according to the RNeasy Mini Kit protocol. An
on-column DNaseI digestion (79254, QIAGEN, Valencia,
CA, USA) was performed following the handbook for the
RNeasy Mini Kit. The quality of the isolated RNA was
determined with a NanoDrop ND 1000 (NanoDrop Tech-
nologies, Delaware, USA) and a Bioanalyzer 2100 (Agi-
lent, Waldbronn, Germany). Only those samples with a
260 nm/280 nm ratio between 1.8 – 2.1 and a 28S/18S
ratio within 1.5 – 2 were processed further.
cRNA preparation
RNA samples (1 μg) were reverse-transcribed into double-
stranded cDNA with One-Cycle cDNA Synthesis Kit
(Affymetrix Inc., P/N 900431, Santa Clara, CA). The dou-
ble-stranded cDNA was purified using a Sample Cleanup
Module (Affymetrix Inc., P/N 900371, Santa Clara, CA).
The purified double-stranded cDNA was in vitro tran-
scribed in the presence of biotin-labeled nucleotides using
an IVT Labeling Kit (Affymetrix Inc., P/N 900449, Santa
Clara, CA). The biotinylated cRNA was purified using a
Sample Cleanup Module (Affymetrix Inc., P/N 900371,
Santa Clara, CA) and its quality and quantity was deter-
mined using NanoDrop ND 1000 and Bioanalyzer 2100.
Array hybridization
Biotin-labeled cRNA samples (13 μg) were fragmented
randomly to 35–200 bp at 94°C in Fragmentation Buffer
(Affymetrix Inc., P/N 900371, Santa Clara, CA) and were
mixed in 300 μl of hybridization buffer containing a
hybridization Control cRNA and Control Oligo B2
(Affymetrix Inc., P/N 900454, Santa Clara, CA), 0.1 mg/
ml herring sperm DNA and 0.5 mg/ml acetylated bovine
serum albumin in 2-(4-morpholino)-ethane sulfonic acid
(MES) buffer, pH 6.7, before hybridization to Affymetrix-
GeneChip® Human Genome U133 Plus 2.0 arrays for 16
h at 45°C. Arrays were then washed using an Affymetrix
Fluidics Station 450 FS450_0001 protocol. An Affymetrix
GeneChip Scanner 3000 (Affymetrix Inc., Santa Clara,
CA) was used to measure the fluorescent intensity emitted
by the labeled target.
Statistical analysis
Raw data processing was performed using the Affymetrix
GCOS 1.4 software (Affymetrix Inc., Santa Clara, CA).
After hybridization and scanning, probe cell intensities
were calculated and summarized for the respective probe
sets by means of the MAS5 algorithm [49]. To compare
the expression values of the genes from chip to chip, glo-
bal scaling was performed, which resulted in the normal-
ization of the trimmed mean of each chip to a target
intensity (TGT value) of 500 as detailed in the statistical
algorithms description document from Affymetrix [50].
Quality control measures were considered before per-
forming the statistical analysis. These included adequate
scaling factors (between 1 and 3 for all samples) and
appropriate numbers of present calls calculated by appli-
cation of a signed-rank call algorithm [51]. The efficiency
of the labeling reaction and the hybridization perform-
ance were controlled using the following parameters:
Present calls and optimal 3'/5' hybridization ratios
(around 1) for the housekeeping genes (GAPDH and
ACO7), for the poly-A spike in controls, and the prokary-
otic control (BIOB, BIOC, CREX, BIODN).
Data processing and further analysis
A probe set was considered as expressed ("present") in a
sample if the corresponding detection p-value was below
0.05. For further normalization and analysis the expres-
sion signals were transformed to log-scale. The log-expres-
sion values were normalized such that the average of
expression of those genes expressed in all samples was
identical. Differential expression was assessed for those
probe sets that were considered present in at least four
samples. By this we discarded the "absent" probe sets that
would unnecessarily inflate the number of false positives.
A probe set was considered significantly differentially
expressed if the p-value computed by Student's t-test on
the log-intensity data was below 0.01. Gene ontology
(GO) analysis was done with the ermineJ software pro-BMC Genomics 2009, 10:199 http://www.biomedcentral.com/1471-2164/10/199
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gram [35] where we used the standard overrepresentation
analysis that is based on Fisher's Exact test. We considered
the significantly up- and down-regulated genes separately
and searched for the GO categories where these genes are
significantly overrepresented. Pathways, processes and
disease analyses of significantly regulated genes were per-
formed using MetaCore (GeneGo, St. Joseph, MI, USA).
Accession number
The Affymetrix microarray related data were submitted to
Gene Expression Omnibus (GEO) under accession
number: [GSE11783].
Histopathology data of urinary bladder tissue
At surgery, biopsies of approximately 20 mm3 in size were
submerged in buffered formalin. After the dehydration
procedure the tissue was embedded in paraffin. At least
three serial sections of 5 to 7 μm thickness were then cut
with a horizontal microtome. The slides were stained with
hematoxylin and eosin (HE) or Giemsa and Elastin van
Gieson following standard procedures [52], and were ana-
lyzed by the Mirax-System (Carl Zeiss AG, Feldbach, Swit-
zerland).
DNA isolation and PCR analysis of potential pathogens
DNA isolation from bladder biopsies and subsequent
PCR analyses were performed by standard validated tech-
niques at IMD Institute for Medical and Molecular Diag-
nostics Ltd in Zurich, Switzerland. The following
pathogens were tested: Chlamydia trachomatis, Helico-
bacter pylori, Herpes simplex virus, Varicella/Zoster virus,
Borrelia burgdorferi, Ureaplasma urealyticum or Myco-
plasma genitalium. Also, PCR amplification of the con-
served region of bacterial 16S rRNA genes was performed.
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Additional file 1
Matrix of 31,579 present probe sets against six healthy, five ni and 
five ulcer samples. Statistical requirement: One probe set needed to be 
present (detection p-value < 0.05) in at least four of the arrays 4 ni, 12 
ni, 13 ni, 14 ni, 15 ni, 2 healthy, 5 healthy, 7 healthy, 9 healthy, 10 
healthy, 11 healthy. The numbers give the expression values relative to the 
average of the healthy controls. The values are not logarithmic.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-199-S1.xls]
Additional file 2
Matrix of the 3,618 significant probe sets and the corresponding cal-
culated log2 ratios, p-values and FDRs of the t-test. Probe sets that are 
significant between the ni and the healthy groups were defined as having 
p-values < 0.01, the individual FDRs ranged from 3.5% to 8.7%. The 
table has been sorted starting with the probe set having the best (the low-
est) p-value.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-199-S2.xls]
Additional file 3
Matrix of the 3,618 significant probe sets against the the six healthy, 
five ni and five ulcer samples. The numbers give the log2 ratio of the 
expression values of the individual IC samples to the average of the healthy 
controls. To make a ranking list of all probe sets, the five ni data sets of 
each probe set were averaged ("Avg log2Ratio ni over healthy"). From this 
number, the overexpression was calculated. Then, the table was sorted 
starting with the probe set having the highest overexpression. Probe sets 
that were more than 2-fold up- or down-regulated have been marked in 
color. In total, there were 1,957 probe sets.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-199-S3.xls]
Additional file 4
Matrix of the 2,543 significant proteins (MetaCore analysis, GeneGo) 
against five ni samples. The numbers give the log2 ratio of the expression 
values of the individual IC samples to the average of the healthy controls. 
To make a ranking list of all proteins, the five ni data sets of each protein 
have been averaged ("Avg log2Ratio ni-vs-healthy"). From this number, 
the overexpression was calculated. Then, the table was sorted starting with 
the protein having the highest overexpression. Proteins that were more 
than 2-fold up- or down-regulated have been marked in color. In total, 
there were 1,417 proteins.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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